Camrelizumab/tislelizumab/toripalimabCheckpoint inhibitor related pneumonitis: 3 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1986卷 / 1期

关键词：

D O I：

10.1007/s40278-023-51425-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：120 / 120

相关论文

共 50 条

[1] Camrelizumab/tislelizumab/toripalimabMyocarditis: 3 case reports
Reactions Weekly, 2022, 1927 (1) : 150 - 150
[2] Camrelizumab/doxorubicin/pembrolizumabImmune-related pneumonitis: 2 case reports
Reactions Weekly, 2020, 1798 (1) : 70 - 70
[3] Camrelizumab/catequentinibElevated alanine aminotransferase, pneumonitis and hypertension: 3 case reports
Reactions Weekly, 2024, 2024 (1) : 110 - 110
[4] Camrelizumab/prednisoneCheckpoint inhibitor-related pneumonitis and lack of efficacy following drug-interaction: 2 case reports
Reactions Weekly, 2023, 1972 (1) : 112 - 112
[5] Camrelizumab/nimotuzumabImmune-related pneumonitis: case report
Reactions Weekly, 2021, 1871 (1) : 107 - 107
[6] Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature
Li, Ling
Lou, Anqi
Yu, Junxian
ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (07) : 8460 - 8466
[7] Everolimus/temozolomideDrug related pneumonitis: 3 case reports
Reactions Weekly, 2016, 1588 (1) : 124 - 124
[8] Nivolumab/pembrolizumabImmune checkpoint inhibitor-related pneumonitis: 4 case reports
Reactions Weekly, 2020, 1832 (1) : 228 - 228
[9] Multiple drugsCheckpoint inhibitor related pneumonitis and cytomegalovirus reactivation: 12 case reports
Reactions Weekly, 2021, 1846 (1) : 209 - 209
[10] Camrelizumab/nivolumabVarious toxicities: 3 case reports
Reactions Weekly, 2021, 1840 (1) : 99 - 99

← 1 2 3 4 5 →